Search results
Jun 28, 2017 · Since resource use and cost of breast cancer defines cost-effectiveness of screening, reviews will be also included if they (1) focus on a female population older than 18 years old, diagnosed with breast cancer at any stage and with average risk of disease progression; (2) include common treatment approaches (containing surgeries, radiation ...
- O. Mandrik, O. Mandrik, O. I. Ekwunife, O. I. Ekwunife, N. Zielonke, F. Meheus, J. L. Severens, S. K...
- 2017
Studies reporting on the cost-effectiveness of cancer screening usually account for quality of life losses and healthcare costs owing to cancer but do not account for future costs and quality of life losses related to competing risks. This study aims to demonstrate the impact of medical costs and quality of life losses of other diseases in the life years gained on the cost-effectiveness of U.S ...
People also ask
How much does breast cancer treatment cost?
Can late-stage breast cancer be treated with a new oncolytic drug?
How much does radiation therapy cost for breast cancer?
What drives the cost difference between early-stage and advanced breast cancer?
May 31, 2023 · e18917 Background: Several clinical trials are comparing the safety and efficacy of risk-based and age-based breast cancer screening. This study aimed to estimate the aggregate yearly cost of screening in the USA for 2019 to 2021 and to project cost of four strategies: annual, biennial, hybrid, and the WISDOM (Women Informed to Screen Depending on Measures of risk) clinical trial’s risk ...
Aug 20, 2015 · Breast cancer, the most common malignancy in women in the United States,1 is a serious disease associated with substantial medical and economic burden. Nearly 3 million US women were living with breast cancer in 2012, and it is estimated that 231,840 women would be newly diagnosed with the disease in 2015.1 Approximately 12.3% of women in the United States will receive a breast cancer ...
- Helen Blumen, Kathryn Fitch, Vincent Polkus
- 2016/02
- 2016
Our analysis uniquely estimates overall NBCCEDP cost-effectiveness of breast cancer screening for low-income, uninsured women. A major strength of our study is that we modified a validated CISNET breast cancer screening model [12, 18-20] and used program-specific cohort and cost information as model inputs. This study also has several limitations.
- Sun Hee Rim, Benjamin T Allaire, Donatus U Ekwueme, Jacqueline W Miller, Sujha Subramanian, Ingrid J...
- 10.1007/s10552-019-01178-y
- 2019
- 2019/08
Jun 23, 2023 · For women diagnosed with stage 0 breast cancer (small, localized tumors), these medical costs totaled $48,477, on average, 6 months after diagnosis. The total rose to $71,909 after 2 years. For ...
Nov 30, 2023 · Background Triple-negative breast cancer (TNBC) is an aggressive and therapy-resistant form of breast cancer with a significant economic burden on patients and healthcare systems. Therefore, we completed a systematic review to classify and synthesize the literature on the direct and indirect costs of TNBC. Methods Databases including ISI Web of Science, Scopus, PubMed, and Google Scholar were ...
